212 related articles for article (PubMed ID: 34312479)
1. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.
Koelsche C; Benhamida JK; Kommoss FKF; Stichel D; Jones DTW; Pfister SM; Heilig CE; Fröhling S; Stenzinger A; Buslei R; Mentzel T; Baumhoer D; Ladanyi M; Antonescu CR; Flucke U; Gorp JV; Bode-Lesniewska B; Deimling AV; Mechtersheimer G
Mod Pathol; 2021 Dec; 34(12):2122-2129. PubMed ID: 34312479
[TBL] [Abstract][Full Text] [Related]
2. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
3. MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
Jimbo N; Komatsu M; Itoh T; Hirose T
Cardiovasc Pathol; 2019; 43():107142. PubMed ID: 31442826
[TBL] [Abstract][Full Text] [Related]
4. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
5. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas.
Neuville A; Collin F; Bruneval P; Parrens M; Thivolet F; Gomez-Brouchet A; Terrier P; de Montpreville VT; Le Gall F; Hostein I; Lagarde P; Chibon F; Coindre JM
Am J Surg Pathol; 2014 Apr; 38(4):461-9. PubMed ID: 24625414
[TBL] [Abstract][Full Text] [Related]
6. Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.
Giner F; Machado I; Rubio-Martínez LA; López-Guerrero JA; Claramunt-Alonso R; Navarro S; Ferrández A; Mayordomo-Aranda E; Llombart-Bosch A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108696
[TBL] [Abstract][Full Text] [Related]
7. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery.
Bode-Lesniewska B; Zhao J; Speel EJ; Biraima AM; Turina M; Komminoth P; Heitz PU
Virchows Arch; 2001 Jan; 438(1):57-65. PubMed ID: 11213836
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
9. Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis.
Cho H; Song IH; Jo U; Jeong JS; Koo HJ; Yang DH; Jung SH; Song JS; Cho KJ
Cancer Med; 2023 Aug; 12(16):16815-16828. PubMed ID: 37395142
[TBL] [Abstract][Full Text] [Related]
10. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications.
Kommoss FK; Chang KT; Stichel D; Banito A; Jones DT; Heilig CE; Fröhling S; Sahm F; Stenzinger A; Hartmann W; Mechtersheimer G; Sinn HP; Schmidt D; Kommoss F; von Deimling A; Koelsche C
J Pathol Clin Res; 2020 Jul; 6(3):178-184. PubMed ID: 32352245
[TBL] [Abstract][Full Text] [Related]
11. DDIT3-amplified or low-polysomic pleomorphic sarcomas without MDM2 amplification: Clinicopathological review and immunohistochemical profile of nine cases.
Mori T; Iwasaki T; Sonoda H; Kawaguchi K; Tomonaga T; Furukawa H; Sato C; Shiraishi S; Taguchi K; Tamiya S; Yoneda R; Oshiro Y; Matsunobu T; Abe C; Kuboyama Y; Ueki N; Kohashi K; Yamamoto H; Nakashima Y; Oda Y
Hum Pathol; 2024 Mar; 145():56-62. PubMed ID: 38401716
[TBL] [Abstract][Full Text] [Related]
12. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors.
Zhao J; Roth J; Bode-Lesniewska B; Pfaltz M; Heitz PU; Komminoth P
Genes Chromosomes Cancer; 2002 May; 34(1):48-57. PubMed ID: 11921282
[TBL] [Abstract][Full Text] [Related]
13. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
[TBL] [Abstract][Full Text] [Related]
14. Primary cardiac dedifferentiated liposarcoma with homologous and heterologous differentiation: a case report.
He D; Chen M; Chen H; Liao D; Wang X; Zhang Z; Zhang H
Int J Clin Exp Pathol; 2015; 8(8):9662-6. PubMed ID: 26464734
[TBL] [Abstract][Full Text] [Related]
15. Specific amplifications and copy number decreases during human neural stem cells differentiation towards astrocytes, neurons and oligodendrocytes.
Fischer U; Kim E; Keller A; Meese E
Oncotarget; 2017 Apr; 8(16):25872-25884. PubMed ID: 28415661
[TBL] [Abstract][Full Text] [Related]
16. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
17. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
[TBL] [Abstract][Full Text] [Related]
18. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
[TBL] [Abstract][Full Text] [Related]
19. MDM4 amplification in atypical lipomatous tumors/well-differentiated liposarcoma: Private event or alternative oncogenic mechanism?
Gruel N; El Zein S; Tzanis D; Nicolas N; Maraval A; Fieffe C; Bonvalot S; Caly M; Fuhrmann L; Ait Rais K; Jovelin S; Bonnet C; Pierron G; Watson S
Genes Chromosomes Cancer; 2023 Jun; 62(6):367-372. PubMed ID: 36744846
[TBL] [Abstract][Full Text] [Related]
20. Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.
Zhang W; McElhinny A; Nielsen A; Wang M; Miller M; Singh S; Rueger R; Rubin BP; Wang Z; Tubbs RR; Nagle RB; Roche P; Wu P; Pestic-Dragovich L
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):54-61. PubMed ID: 20881839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
